Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adlai Nortye Ltd. - American Depositary Shares (NQ:ANL)

7.190 +0.200 (+2.86%)
Streaming Delayed Price Updated: 10:01 AM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adlai Nortye Ltd. - American Depositary Shares

News headline image
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye to Participate in Upcoming Investor Conferences
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of Directors 
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
From Adlai Nortye Ltd.
Via GlobeNewswire
News headline image
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
From Adlai Nortye Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.